恩替卡韦治疗慢性乙型肝炎合并肝脂肪变的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (31 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Entecavir in the treatment of chronic hepatitis B with hepatic steatosis.Methods Eighty patients with chronic hepatitis B and hepatic steatosis admitted to our hospital from February to November in 2017 were aelected as subjects.The patients were equally divided into observation group and control group according to computer randomization.In the observation group,Entecavir was used,and in the control group,Rosuvastatin was adopted.The serum alanine aminotransferase (ALT),hepatitis B virus-DNA,blood lipid index and therapeutic effect were compared between the two groups.Results After treatment,the serum ALT and hepatitis B virus-DNA of patients in the observation group were lower than those in the control group,the differences were statistically significant(P＜0.05).After treatment,the total cholesterol,triglyceride and low density lipoprotein cholesterol in the observation group were lower than those in the control group,and the high density lipoprotein cholesterol was higher than that in the control group,the differences were statistically significant(P＜0.05).The total effectiveness rate of the observation group was higher than that of the control group with a statistical difference (P＜0.05).Conclusion The efficacy of Entecavir in the treatment of chronic hepatitis B with hepatic steatosis is very significant,which can improve the blood lipid index,and is worthy of study.

Key words： Entecavir Treatment Chronic hepatitis B with hepatic steatosis Effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Ran

Cite this article:

LI Ran. Clinical effect of Entecavir in the treatment of chronic hepatitis B combined with hepatic steatosis[J]. 中国当代医药, 2019, 26(3): 110-112.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2019/V26/I3/110

[1]	陈建能，庄群瑛，陈碧芬，等.慢性乙型肝炎合并肝脂肪变的影响因素[J].中华传染病杂志，2013，31（3）：160-165.
[2]	吴艳琴，沈黎俊，于集虹，等.恩替卡韦治疗慢性乙型肝炎合并肝脂肪变的效果评价[J].临床肝胆病杂志，2017，33（5）：849-852.
[3]	陈梅琴，吴金明，陈娟，等.合并非酒精性脂肪性肝病对e抗原阳性慢性乙型肝炎患者核苷类似物抗病毒疗效的影响[J].中华传染病杂志，2014，32（3）：158-161.
[4]	应若素，陈燕宇，卓丽，等.慢性乙型肝炎合并非酒精性脂肪性肝病患者抗病毒治疗的疗效探讨[J].临床肝胆病杂志，2013，29（8）：603-606.
[5]	刘淑娥，郝美娜，任亚楠，等.慢性乙型肝炎患者合并脂肪肝导致单纯抗病毒治疗生物化学应答不佳诊疗分析[J].中华肝脏病杂志，2015，23（5）：333-338.
[6]	宋春霞，赵艳，阎志欣，等.恩替卡韦治疗慢性乙型肝炎合并脂肪肝临床疗效观察[J].中国煤炭工业医学杂志，2014，17（8）：1257-1259.
[7]	陆建国.聚乙二醇干扰素α-2a治疗慢性乙型肝炎合并脂肪肝的临床疗效[J].胃肠病学和肝病学杂志，2014，23（3）：329-332.
[8]	朱礼尧，周建，冯伟广，等.恩替卡韦治疗单纯慢性乙型肝炎和合并非酒精性脂肪性肝病患者的效果比较[J].中华传染病杂志，2016，34（6）：362-363.
[9]	武瑞，娄国强，施军平，等.肝细胞脂肪变对干扰素抗乙型肝炎病毒治疗应答的影响及相关因素研究[J].医学研究杂志，2014，43（11）：103-106.
[10]	张志侨，王功遂，康凯夫，等.慢性乙型肝炎合并非酒精性脂肪性肝病的临床特征分析[J].临床肝胆病杂志，2015，31（7）：1063-1067.
[11]	蒋厚勋.疏肝消脂汤治疗慢性乙型肝炎合并非酒精性脂肪肝 49 例[J].河南中医，2015，35（5）：997-999.
[12]	蔡乐斌，陶娜，陈娜，等.恩替卡韦联合维生素E治疗慢性乙型肝炎合并非酒精脂肪肝的临床观察[J].现代医院，2017，17（5）：732-734.
[13]	杨年欢，袁国盛，周宇辰，等.恩替卡韦联合复方鳖甲软肝片治疗慢性乙型肝炎肝纤维化96周的临床疗效[J].南方医科大学学报，2016，36（6）：775-779.
[14]	刘海涛，施家希，罗丹，等.中医药辨证治疗慢性乙型肝炎用药规律文献研究[J].中医杂志，2016，57（16）：1421-1425.
[15]	张弦，蒋伟，甘建和，等.恩替卡韦治疗慢性乙型肝炎的疗效及其对外周血调节性T细胞水平的影响[J].山东医药，2016，56（34）：42-44.